• Sermonix Pharmaceuticals is a specialty pharmaceutical company with targeted focus towards bringing new and emerging late-stage women’s health products through clinical development, regulatory approval, and commercialization.

Sermonix Pharmaceuticals is a specialty pharmaceutical company with targeted focus towards bringing new and emerging late-stage women’s health products through clinical development, regulatory approval, and commercialization.

Our lead candidate is Lasofoxifene

 

Unique Selective Estrogen Receptor Modulator (SERM) in Phase 3 Clinical Trials

Extensively studied in post-menopausal osteoporosis treatment and prevention and vulvovaginal atrophy (VVA)

 

About

Sermonix was founded in late 2014 by David Portman, MD, a leading clinical researcher and expert in women’s health, menopause and selective estrogen receptor modulators.

 
Read more

Lasofoxifene

Extensively studied for the treatment and prevention of postmenopausal osteoporosis and treating symptoms of vulvovaginal atrophy (VVA).

 
Read more

News

Sermonix announces the signing of a license agreement with Ligand Pharmaceuticals Incorporated (LGND LLC) for the development and commercialization of oral lasofoxifene.

 
Read more
Focused on bringing new and emerging late-stage women’s health productsLEARN MORE